Edition:
United States

Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

22.48USD
17 Aug 2017
Change (% chg)

-- (--)
Prev Close
$22.48
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
227,348
52-wk High
$27.07
52-wk Low
$7.20

Select another date:

Tue, Aug 15 2017

BRIEF-Omeros announces pricing of public offering of common stock

* Omeros announces pricing of public offering of common stock

BRIEF-Omeros announces public offering of common stock

* Says offering 3.00 million common shares Source text for Eikon: Further company coverage:

BRIEF-Omeros Corporation Q2 loss per share $0.33

* Omeros corporation reports second quarter 2017 financial results

BRIEF-FDA grants orphan drug designation to Omeros’ OMS721

* FDA grants Orphan Drug Designation to Omeros’ OMS721 for treatment of IGA Nephropathy

BRIEF-Omeros says FDA grants breakthrough therapy designation to OMS721 for treatment of IgA Nephropathy

* FDA grants breakthrough therapy designation to Omeros’ MASP-2 inhibitor OMS721 for the treatment of IgA Nephropathy

BRIEF-Omeros completes IGA nephropathy cohort in OMS721 phase 2 clinical trial

* Omeros announces completion of IGA nephropathy cohort in OMS721 phase 2 clinical trial

BRIEF-Omeros reports Q1 revenue $12.3 million

* Omeros Corporation reports first quarter 2017 financial results

BRIEF-Omeros reports more positive data in OMS721 phase 2 trial in renal diseases

* Omeros reports more positive data in OMS721 phase 2 trial in renal diseases

BRIEF-Omeros reports additional positive results from OMS721 Phase 2 trial

* Omeros reports additional positive results from OMS721 phase 2 trial in patients with stem cell transplant-associated thrombotic microangiopathy

Select another date: